| Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology MH Shah, WS Goldner, AB Benson, E Bergsland, LS Blaszkowsky, ... Journal of the National Comprehensive Cancer Network 19 (7), 839-868, 2021 | 319 | 2021 |
| Classification of pulmonary neuroendocrine tumors: new insights G Pelosi, A Sonzogni, S Harari, A Albini, E Bresaola, C Marchiò, F Massa, ... Translational lung cancer research 6 (5), 513, 2017 | 142 | 2017 |
| Lifestyle factors in cancer survivorship: where we are and where we are headed N Vijayvergia, CS Denlinger Journal of personalized medicine 5 (3), 243-263, 2015 | 129 | 2015 |
| Survivorship in non–small cell lung cancer: challenges faced and steps forward N Vijayvergia, PC Shah, CS Denlinger Journal of the National Comprehensive Cancer Network 13 (9), 1151-1161, 2015 | 120 | 2015 |
| Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites WS El-Deiry, N Vijayvergia, J Xiu, A Scicchitano, B Lim, NS Yee, ... Cancer biology & therapy 16 (12), 1726-1737, 2015 | 100 | 2015 |
| Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study N Vijayvergia, PM Boland, E Handorf, KS Gustafson, Y Gong, HS Cooper, ... British journal of cancer 115 (5), 564-570, 2016 | 99 | 2016 |
| Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial OE Rahma, G Yothers, TS Hong, MM Russell, YN You, W Parker, ... JAMA oncology 7 (8), 1225-1230, 2021 | 96 | 2021 |
| Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials N Vijayvergia, A Dasari, M Deng, S Litwin, T Al-Toubah, RK Alpaugh, ... British journal of cancer 122 (9), 1309-1314, 2020 | 96 | 2020 |
| Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer N Vijayvergia, R Mehra Cancer chemotherapy and pharmacology 74, 437-446, 2014 | 46 | 2014 |
| NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results. TJ George, G Yothers, TS Hong, MMG Russell, YN You, W Parker, ... Journal of Clinical Oncology 37 (15_suppl), 3505-3505, 2019 | 35 | 2019 |
| A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells EM Matthew, L Zhou, Z Yang, DT Dicker, SL Holder, B Lim, R Harouaka, ... Oncotarget 7 (4), 3662, 2016 | 35 | 2016 |
| BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations S Deihimi, A Lev, M Slifker, E Shagisultanova, Q Xu, K Jung, ... Oncotarget 8 (25), 39945, 2017 | 29 | 2017 |
| NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results. OE Rahma, G Yothers, TS Hong, MMG Russell, YN You, W Parker, ... Journal of Clinical Oncology 39 (3_suppl), 8-8, 2021 | 19 | 2021 |
| A subset of large cell neuroendocrine carcinomas in the gastroenteropancreatic tract may evolve from pre-existing well-differentiated neuroendocrine tumors G Pelosi, F Bianchi, E Dama, J Metovic, M Barella, A Sonzogni, A Albini, ... Endocrine Pathology, 1-12, 2021 | 18 | 2021 |
| Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). N Vijayvergia, A Dasari, EA Ross, E Dotan, DM Halperin, IA Astsaturov, ... Journal of Clinical Oncology 36 (15_suppl), 4104-4104, 2018 | 18 | 2018 |
| Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience N Vijayvergia, E Dotan, K Devarajan, K Hatahet, F Rahman, J Ricco, ... Journal of geriatric oncology 6 (6), 454-461, 2015 | 18 | 2015 |
| Feasibility of fitness tracker usage to assess activity level and toxicities in patients with colorectal cancer WH Ward, CR Meeker, E Handorf, MV Hill, M Einarson, RK Alpaugh, ... JCO Clinical Cancer Informatics 5, 125-133, 2021 | 15 | 2021 |
| NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple … CE Geyer, S Loibl, P Rastogi, S Seiler, JP Costantino, N Vijayvergia, ... Journal of Clinical Oncology 36 (15_suppl), TPS603-TPS603, 2018 | 15 | 2018 |
| Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer N Vijayvergia, T Li, YN Wong, MJ Hall, SJ Cohen, E Dotan Cancer 122 (20), 3191-3198, 2016 | 14 | 2016 |
| Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC). TJ George, G Yothers, OE Rahma, TS Hong, MMG Russell, YN You, ... Journal of Clinical Oncology 41 (4_suppl), 7-7, 2023 | 11 | 2023 |
